The Fifth Annual IO Combinations 360° will take place October 1-2, 2020, at Le Meridien, Philadelphia, PA.
The Focused Ultrasound Foundation (FUSF) hosts a special conversation with Jill O’Donnell-Tormey, Ph.D., CEO of the Cancer Research Institute (CRI), and Jessica Foley, Ph.D., chief scientific officer of FUSF.
CRI's Vanessa Lucey, Ph.D., MBA, speaks on the "ASCO Preview" webinar on May 27, 2020, at 3 p.m. ET.
CRI's Vanessa Lucey, Ph.D., MBA, speaks on the "Investor Panel" on May 27, 2020, at 12 p.m. CT.
CRI's Vanessa Lucey, Ph.D., MBA, speaks on the "Investing into Oncology" and "Oncology Modalities Facing Off" panels.
CRI’s Vanessa Lucey, Ph.D., MBA, speaks on the "Landscape and Evolution of the Marketplace" panel on February 27, 2020.
CRI's Vanessa Lucey, Ph.D., discusses the immuno-onocology landscape in this webinar for the biotechnology industry.
On December 4, CRI's Vanessa Hubbard-Lucey, Ph.D., MBA, is giving a talk on "Challenges and opportunities in designing immuno-oncology trials: A non-profit perspective."
CRI's Vanessa Lucey is presenting a poster on our prostate cancer clinical trial in conjunction with our partners.
CRI's Jun Tang, Ph.D., senior manager, CRI Venture Fund and Clinical Accelerator, is presenting the latest update on the PD1/L1 landscape.
Drs. Jill O'Donnell-Tormey and Vanessa M. Lucey are participating in panel discussions at Cancer Progress.
*Immunotherapy results may vary from patient to patient.
Cancer Research Institute | National Headquarters
29 Broadway, Floor 4 | New York, NY 10006-3111
(800) 992-2623(212) 832-9376Staff Directory
CRI Fellow Dr. Tim Fessenden of MIT shared his day with the CRI social community on Friday, June 26.
CRI hosted esteemed immunologists Carl June, Miriam Merad, and E. John Wherry to highlight immunotherapy’s pivotal role in addressing the COVID-19 pandemic.